We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+44.51%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$350M
AUM Growth
+$53.9M
Cap. Flow
+$2.7M
Cap. Flow %
0.77%
Top 10 Hldgs %
33.5%
Holding
108
New
29
Increased
39
Reduced
21
Closed
18

Top Buys

Rank Stock Value
1
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$9.42M
2
NUVL
Nuvalent
NUVL
+$7.29M
3
BIIB icon
Biogen
BIIB
+$6.21M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$4.88M
5
TERN
Terns Pharmaceuticals
TERN
+$4.56M

Top Sells

Rank Stock Value
1
VCYT icon
Veracyte
VCYT
+$10.8M
2
APEN
Apollo Endosurgery, Inc.
APEN
+$6.26M
3
AKRO
Akero Therapeutics
AKRO
+$5.48M
4
COGT icon
Cogent Biosciences
COGT
+$5.3M
5
NKTX icon
Nkarta
NKTX
+$4.77M

Sector Composition

Rank Sector Weight
1 Healthcare 79.93%
2 Technology 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLMD icon
101
PUT
Relmada Therapeutics
RLMD
$562M
– –
-393,000
Closed -$14.5M
NGM
102
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
– –
-94,517
Closed -$1.24M
KRTX
103
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-10,323
Closed -$2.32M
MRTX
104
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-42,500
Closed -$2.97M
MRTX
105
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-10,220
Closed -$714K
ISEE
106
PUT
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-443,100
Closed -$7.95M
APEN
107
DELISTED
Apollo Endosurgery, Inc.
APEN
– –
-1,136,206
Closed -$6.26M
RCOR.WS
108
DELISTED
Renovacor, Inc. Warrants, entitling the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11. 50 per whole share
RCOR.WS
– –
-104,828
Closed -$8K
1 2 3 4
5

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return

Silverarc Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Silverarc Capital Management held 108 positions worth $350M, up 18% from $296M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Silverarc Capital Management's Q4 2022 filing shows 29 new, 39 increased, 21 reduced and 18 closed positions. Its largest new stake was CinCor Pharma, Inc. Common Stock: 395,382 shares worth $4.86M. The largest sale was Veracyte, an estimated $10.8M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 77% a quarter earlier, followed by Technology.

  • Silverarc Capital Management's largest Q4 2022 buy was CinCor Pharma, Inc. Common Stock: 395,382 shares worth $4.86M.
  • Silverarc Capital Management added most to Nuvalent in Q4 2022, an estimated $7.29M increase.
  • Silverarc Capital Management's biggest Q4 2022 reduction was Veracyte, cutting an estimated $10.8M.
  • Silverarc Capital Management fully exited Apollo Endosurgery, Inc. in Q4 2022, selling an estimated $6.26M.
  • Silverarc Capital Management's ten largest holdings make up 33% of its $350M portfolio in Q4 2022.
  • Silverarc Capital Management opened 29 new positions and closed 18 in Q4 2022.
  • Silverarc Capital Management's portfolio value rose 18% quarter-over-quarter to $350M.

Based on Silverarc Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.